LncRNA JHDM1D-AS1 Is a key biomarker for progression and modulation of gemcitabine sensitivity in bladder cancer cells.

dc.contributor.authorPereira, Isadora Oliveira Ansaloni
dc.contributor.authorSilva, Glenda Nicioli da
dc.contributor.authorAlmeida, Tamires Cunha
dc.contributor.authorLima, Ana Paula Braga
dc.contributor.authorSávio, André Luiz Ventura
dc.contributor.authorLeite, Katia Ramos Moreira
dc.contributor.authorSalvadori, Daisy Maria Fávero
dc.date.accessioned2023-10-11T20:22:42Z
dc.date.available2023-10-11T20:22:42Z
dc.date.issued2023pt_BR
dc.description.abstractLong non-coding RNAs are frequently found to be dysregulated and are linked to carcinogenesis, aggressiveness, and chemoresistance in a variety of tumors. As expression levels of the JHDM1D gene and lncRNA JHDM1D-AS1 are altered in bladder tumors, we sought to use their combined expression to distinguish between low-and high-grade bladder tumors by RTq-PCR. In addition, we evaluated the functional role of JHDM1D-AS1 and its association with the modulation of gemcitabine sensitivity in high-grade bladder-tumor cells. J82 and UM-UC-3 cells were treated with siRNA-JHDM1D-AS1 and/or three concentrations of gemcitabine (0.39, 0.78, and 1.56 µM), and then submitted to cytotoxicity testing (XTT), clonogenic survival, cell cycle progression, cell morphology, and cell migration assays. When JHDM1D and JHDM1D-AS1 expression levels were used in combination, our findings indicated favorable prognostic value. Furthermore, the combined treatment resulted in greater cytotoxicity, a decrease in clone formation, G0/G1 cell cycle arrest, morphological alterations, and a reduction in cell migration capacity in both lineages compared to the treatments alone. Thus, silencing of JHDM1D-AS1 reduced the growth and proliferation of high-grade bladder-tumor cells and increased their sensitivity to gemcitabine treatment. In addition, the expression of JHDM1D/JHDM1D-AS1 indicated potential prognostic value in the progression of bladder tumors.pt_BR
dc.identifier.citationPEREIRA, I. O. A. et al. LncRNA JHDM1D-AS1 Is a key biomarker for progression and modulation of gemcitabine sensitivity in bladder cancer cells. Molecules, v. 28, artigo 2412, 2023. Disponível em: <https://www.mdpi.com/1420-3049/28/5/2412>. Acesso em: 01 ago. 2023.pt_BR
dc.identifier.doihttps://doi.org/10.3390/molecules28052412pt_BR
dc.identifier.issn1420-3049
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/17571
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Fonte: PDF do artigo.pt_BR
dc.subjectBladder cancerpt_BR
dc.subjectLong non-coding RNAspt_BR
dc.titleLncRNA JHDM1D-AS1 Is a key biomarker for progression and modulation of gemcitabine sensitivity in bladder cancer cells.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
ARTIGO_LncRNAJHDM1D.pdf
Tamanho:
3.21 MB
Formato:
Adobe Portable Document Format
Descrição:
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: